News

Happy New Year From InvivoSciences

InvivoSciences wishes all a happy and prosperous new year!

InvivoSciences Sponsors Tricky Science Night at LCEC

InvivoSciences was one of the sponsors supporting the Lussier Community Education Center’s Halloween-themed science night in Madison, WI on October 30, 2015.

CEO to Present at Biotech and The Law Expo

InvivoSciences’ CEO/Co-Founder, Ayla Annac, has been invited to speak at the 2016 Biotech and The Law Global Conference & Expo. Her presentation, “Therapeutic Advancement: Developing Drug Discovery Platforms,” will discuss InvivoSciences’ continuing role in the development of precision medicine, particularly the impact of our 3D human tissue model systems on toxicity studies. She will be presenting on…
Read more

InvivoSciences Featured in MedTech Dealmakers

InvivoSciences was featured in the October 2015 issue of MedTech Dealmakers. The article is titled “Predicting Cardiotoxicity with Engineereed 3D Human Cardiac Tissue Models.” InvivoSciences harnesses human induced pluripotent stem cells to generate patient-specific disease models for drug and diagnostics development.  

InvivoSciences Featured in GEN

Dr. Wakatsuki was interviewed and quoted in the September 2015 GEN article titled, “Feng Shui Basics for 3D Cell Culture.” The author writes about how our engineered heart tissues (EHT) “(bring) practical applications to personalized medicine.”

CSO is presenting at World Preclinical Congress in Boston

InvivoSciences to present at World Preclinical Congress in Boston. InvivoSciences developed an in vitro disease model that recapitulates individual patient’s cardiomyopathy in 3D engineered heart tissues (EHTs) using the patient-derived cells. Automated cell culture and cardiomyocyte-differentiation protocol improved the productivity and reproducibility for generating patient-specific disease models for drug and diagnostics development.

BIOtechNOW featured IVS’s participating BIO Innovation Zone

Later this month in Philadelphia at the BIO International Convention, BIO will be partnering with the National Institutes of Health (NIH) and the National Science Foundation (NSF) to host the 2nd annual, newly-expanded BIO Innovation Zone. The Zone will feature Small Business Innovation Research (SBIR) funded early-stage biotech companies.

BIO Investor Forum Company Snapshot: InvivoSciences

BIO Investor Forum Company Snapshot: InvivoSciences What is your company’s lead product or technology? InvivoSciences, Inc. (IVS) is a leading developer of proprietary human 3D cell/tissue culture models for highly-predictive, multi-parameter phenotypic assays both in pharmacology safety & discovery screening and in personalized and regenerative medicine. IVS’s Functional 3D tissue models recapitulate the physiological properties…
Read more

InvivoSciences, Inc. (IVS) is one of the selected companies in NIH’s Innovation Zone at the 2014 BIO International Convention

NIH has partnered with the Biotechnology Industry Organization (BIO) to provide selected SBIR grantees premier visibility at the BIO International Convention. InvivoSciences (IVS) is one of the selected NIH Innovation Zone companies interacting with potential investors and business partners. BIO International Convention is the world’s largest conference attracting 15,000 biotech leaders from 65 countries. This…
Read more

BMG LABTECH and InvivoSciences, Inc. Initiate Market Collaboration To Accelerate Drug Discovery in Engineered 3D Tissues

The Microplate Reader Company – and InvivoSciences, Inc. – a leader in stem cell tissue engineering providing a novel solution in first-in-class drug discovery – announced today a strategic collaboration to market the time-dependent fluorescent assessment of engineered 3D heart tissues using advanced microplate reader technologies. Employing an automated system, 3D heart tissues are fabricated…
Read more